文献速递临床试验与 GCP流行病学与生物统计

Gefapixant治疗难治性或不明原因慢性咳嗽的疗效与耐受性:系统评价与剂量-反应Meta分析

Efficacy and Tolerability of Gefapixant for Treatment of Refractory or Unexplained Chronic Cough: A Systematic Review and Dose-Response Meta-Analysis.
PubMed 文献 · JAMA · 2023-01-01

该系统评价与剂量-反应Meta分析纳入9项随机临床试验共2980例难治性或不明原因慢性咳嗽患者,评估Gefapixant的疗效与耐受性。与安慰剂相比,Gefapixant 45 mg每日两次对清醒期咳嗽频率、咳嗽严重度和咳嗽特异性生活质量有小幅改善,但增加治疗相关不良事件和味觉相关不良事件。

要点

  • Gefapixant 45 mg每日两次对清醒期咳嗽频率的降低幅度为17.6%(95%CI 10.6%-24.0%),证据确定性中等。
  • Gefapixant 45 mg每日两次对100-mm VAS咳嗽严重度的平均差为-6.2 mm(95%CI -4.1至-8.4),证据确定性高。
  • Gefapixant 45 mg每日两次增加治疗相关不良事件(每100例患者多32例,95%CI 13-64)和味觉相关不良事件(每100例患者多32例,95%CI 22-46)。

核心结论

  • 与安慰剂相比,Gefapixant 45 mg口服每日两次对咳嗽频率、咳嗽严重度和咳嗽特异性生活质量有适度改善,但增加味觉相关不良事件。

研究设计与样本

  • 系统评价与剂量-反应Meta分析,检索MEDLINE、Embase、Cochrane对照试验中心注册库和Web of Science(2014年11月至2023年7月),纳入平行或交叉设计的随机临床试验,主要分析纳入9项随机临床试验共2980例患者。

主要发现

  • 与安慰剂相比,Gefapixant 45 mg每日两次使清醒期咳嗽频率降低17.6%(95%CI 10.6%-24.0%),证据确定性中等。
  • 与安慰剂相比,Gefapixant 45 mg每日两次对100-mm VAS咳嗽严重度的平均差为-6.2 mm(95%CI -4.1至-8.4),证据确定性高。
  • 与安慰剂相比,Gefapixant 45 mg每日两次对LCQ咳嗽特异性生活质量的均差为1.0分(95%CI 0.7-1.4),证据确定性中等。
  • 与安慰剂相比,Gefapixant 45 mg每日两次可能增加治疗相关不良事件(每100例患者多32例,95%CI 13-64),证据确定性中等。
  • 与安慰剂相比,Gefapixant 45 mg每日两次增加味觉相关不良事件(每100例患者多32例,95%CI 22-46),证据确定性高;Gefapixant 15 mg每日两次对味觉相关不良事件有小幅影响(每100例患者多6例,95%CI 5-8),证据确定性高。

关键数值与推荐

  • 咳嗽频率采用VitaloJAK咳嗽监测仪测量,最小重要差异(MID)为20%。
  • 咳嗽严重度采用100-mm视觉模拟量表(VAS)测量,评分越高越严重,MID为30 mm。
  • 咳嗽特异性生活质量采用莱斯特咳嗽问卷(LCQ)测量,评分范围3分(最大损害)至21分(无损害),MID为1.3分。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Gefapixant represents an emerging therapy for patients with refractory or unexplained chronic cough. OBJECTIVE: To evaluate the efficacy and tolerability of gefapixant for the treatment of adults with refractory or unexplained chronic cough. DATA SOURCES: MEDLINE, Embase, Cochrane Central Register of Controlled Trials, and Web of Science from November 2014 to July 2023. STUDY SELECTION: Two reviewers independently screened for parallel and crossover randomized clinical trials (RCTs) that compared, in patients with refractory or unexplained chronic cough, either gefapixant with placebo, or 2 or more doses of gefapixant with or without placebo. DATA EXTRACTION AND SYNTHESIS: Two reviewers independently extracted data. A frequentist random-effects dose-response meta-analysis or pairwise meta-analysis was used for each outcome. The GRADE (Grading of Recommendations, Assessment, Development, and Evaluation) approach was used to rate the certainty in whether patients would perceive the effects as important (greater than the minimal important difference [MID]) or small (less than the MID). MAIN OUTCOMES AND MEASURES: Cough frequency (measured using the VitaloJAK cough monitor; MID, 20%), cough severity (measured using the 100-mm visual analog scale [VAS]; higher score is worse; MID, 30 mm), cough-specific quality of life (measured using the Leicester Cough Questionnaire [LCQ]; score range, 3 [maximal impairment] to 21 [no impairment]; MID, 1.3 points), treatment-related adverse events, adverse events leading to discontinuation, and taste-related adverse events. RESULTS: Nine RCTs including 2980 patients were included in the primary analysis. Compared with placebo, gefapixant (45 mg twice daily) had small effects on awake cough frequency (17.6% reduction [95% CI, 10.6%-24.0%], moderate certainty), cough severity on the 100-mm VAS (mean difference, -6.2 mm [95% CI, -4.1 to -8.4]; high certainty), and cough-specific quality of life on the LCQ (mean difference, 1.0 points [95% CI, 0.7-1.4]; moderate certainty). Compared with placebo, gefapixant (45 mg twice daily) probably caused an important increase in treatment-related adverse events (32 more per 100 patients [95% CI, 13-64 more], moderate certainty) and taste-related adverse events (32 more per 100 patients [95% CI, 22-46 more], high certainty). High-certainty evidence suggests that gefapixant (15 mg twice daily) had small effects on taste-related adverse events (6 more per 100 patients [95% CI, 5-8 more]). CONCLUSIONS AND RELEVANCE: Compared with placebo, gefapixant (45 mg orally twice daily) led to modest improvements in cough frequency, cough severity, and cough-specific quality of life but increased taste-related adverse events.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Kum E, Patel M, Diab N, et al. Efficacy and Tolerability of Gefapixant for Treatment of Refractory or Unexplained Chronic Cough: A Systematic Review and Dose-Response Meta-Analysis. JAMA. 2023. PMID: 37694849. doi:10.1001/jama.2023.18035

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。